GSK and Elegen Team Up to Develop DNA-Based Medicines and Vaccines

SOURCE: Genetic Engineering News

JAN 24, 2024

The multi-year collaboration allows GSK to leverage Elegen’s cell-free synthetic DNA production technology.

Elegen’s ability to produce NGS-verified linear DNA up to 7 kb within a week with error rates as low as 1:70,000 per bp (99.999% per base accuracy) could be an important marker as it tries to establish a leading position in a heated race to deliver what could be the next major medicinal breakthrough.